Critically shortened telomeres are known to be a key limiting factor in successful CAR T-cell immunotherapy, with cells from older patients tending to have shorter telomeres with reduced dividing capacity. As such, these cells are unable to fully eliminate malignancies and provide durable and persistent protection against cancer. So, what if you could lengthen these DNA-protein structures found at the end of chromosomes during the ex-vivo manufacturing of CAR T cells, i.e., before they are put back into the body, so increasing their potency against disease? Newly-launched firm Telos Biotech – a subsidiary company of Cambrian Bio – believes you can, with its patent-protected recombinant protein, Telovance, promising to shake up the cell therapy field.